Pfizer's new crown vaccine Comirnaty's revenue in the first three quarters was US$24.3 billion

On November 2, Pfizer announced its 2021Q3 financial report, with a single quarter revenue of US$24.
094 billion, a year-on-year increase of 134%.
The revenue for the first three quarters was US$57.
653 billion, a year-on-year increase of 91%
.
Pfizer therefore raised its full-year revenue forecast to US$81-82 billion

Pfizer's mRNA new crown vaccine Comirnaty (BNT162b2) has revenue of US$12.
77 billion in the single quarter of 2021Q3, and sales revenue of US$24.
277 billion in the first three quarters.
It is estimated that the annual revenue will be raised from US$33.
5 billion to US$36 billion
.

The rapid increase in Comirnaty sales revenue in the third quarter benefited from the expansion of the vaccinated population.
First, the third dose of booster was authorized by the FDA for emergency use on August 13; secondly, Comirnaty was officially approved by the FDA on August 24, becoming the first The mRNA new crown vaccine officially approved by the regulatory authorities
.
In addition, the FDA on September 23 approved the expansion of the use of Comirnaty intensified needles for people over 65 years of age and high-risk groups

On September 20, Pfizer and BioNTech also announced the results of a phase II/III clinical trial of Comirnaty in children aged 5-11 years, showing good safety and strong neutralizing antibody response
.
Comirnat has obtained emergency use authorization from the FDA for children aged 5-11

Pfizer expects that Comirnaty's production capacity will be expanded to 4 billion doses in 2022, and its annual revenue is estimated to be 29 billion US dollars